Finding the relevance of antimicrobial stewardship for cystic fibrosis

Antimicrobials have revolutionized the treatment of bacterial infections and saved countless lives, but their improper use is associated with increased healthcare costs, antimicrobial toxicity and antimicrobial-related adverse events, and the global emergence of antimicrobial-resistant bacteria. These issues have been addressed in part through antimicrobial stewardship (AMS) programs. Even in cystic fibrosis (CF), while antimicrobial use has been associated with dramatic improvement in clinical outcomes, there are growing concerns related to antimicrobial resistance (AMR) [1] and worries about limited antimicrobial benefit that are shared by patients and healthcare providers.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research